Copyright © 2021, Diaceutics. All rights reserved

Participate in collaborations on DXRX - The Diagnostic Network®

DXRX - The world's first Diagnostic Network

An end-to-end solution for the development and commercialization of precision medicine diagnostics

Learn More about DXRX

The below collaborations on the DXRX platform will be closing soon with limited availability remaining.

To register your interest in joining these FREE collaborations, please choose the collaborations of interest in the form below and a member of our Global Laboratory Team will be in touch.

About Diaceutics

At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - the world’s first Network solution for the development and commercialization of precision medicine diagnostics. Diaceutics has worked on every precision medicine brought to market and provides services to 36 of the world’s leading pharmaceutical companies. We have built the world’s largest repository of diagnostic testing data with a growing network of 2500 labs in 51 countries.

EMQN CIC Colorectal cancer EQA Program

Enrollment onto the accredited CRC EQA module from EMQN

Colorectal cancer is one of the major causes of cancer-related death. Patient survival is highly dependent on the tumor stage at the time of diagnosis and most patients are diagnosed at advanced stages of the disease. This program is being offered for labs undertaking molecular testing for colorectal cancer using FFPE tissue.

  • Receive sponsorship towards participation
  • The opportunity to benchmark yourself with other labs participating in selected collaborations
  • Access to free test materials (slides, blocks) in selected collaborations
  • Contribute towards standardised consistent testing methodologies
Join Now

EMQN CIC Oncopanel EQA program 

Enrollment onto the Oncopanel 20 EQA module for NGS/RT-PCR lung biomarkers testing

Recent therapeutic developments in NGS are revolutionizing biomarker detection in oncology however, only a slow transition towards the use of comprehensive genomic assessment has been observed irrespective, of the fact that many labs are equipped with these NGS platforms.

Join Now

UKNEQAS ICC and ISH Mismatch Repair (MMR) Proteins EQA program

Enrollment onto the international MMR EQA module from UKNEQAS

Germline mutations in DNA MMR proteins are one of the molecular fingerprints of Lynch syndrome; somatic mutations in these proteins are also associated with neoplastic conditions such as colorectal cancer and endometrial cancers. As more cancers are linked to these proteins, their importance as precision medicine biomarkers continues to grow.

Join Now

CPQA NTRK IHC Proficiency Testing

Canadian Pathology Quality Assurance Collaboration

In recent years, NTRK gene fusions have emerged as targets for cancer therapy due to advancing sequencing technologies. Globally, more labs are now testing for NTRK which means there is a growing demand for a robust Proficiency Testing (PT) program in this area. For more information please watch this webinar with CPQA.

Join Now

Closing Date: 30th March 2021

Closing Date: 30th March 2021

Closing Date: *Re-opening in May 2021*

Only 20 places available

Why Join a collaboration on DXRX?

EMQN CIC Breast cancer (somatic mutation testing of PIK3CA) EQA Program

Enrollment onto the BC EQA module from EMQN

Breast cancer is the most frequent cancer among women around the globe. Activating mutations in PIK3CA are found in approximately 30–40% of patients and are associated with endocrine therapy resistance. The role of PIK3CA is becoming increasingly important for HER2+ and TNBC patients. This program is being offered for labs undertaking molecular testing of the PIK3CA gene in breast cancer.

Join Now

Closing Date: 30th March 2021